08-27-2018 – ETBI – EastGate Biotech Signs Definitive Investment and European Licensing Agreement With Nico Innovagroup S.r.l. for Liquid Insulin Mouth Rinse Solution
Non-Dilutive Investment and Product License Includes Licensing Fee and Development Costs WEST CALDWELL, NJ and TORONTO, ON / ACCESSWIRE / August 27, 2018 /Ā EastGate Biotech Corp. (OTC PINK: ETBI), a pharmaceutical company that focuses on innovative technological developments specifically in insulin drug delivery for the treatment of type 2 diabetes, signed a definitive agreement effective August 10th, 2018 with Nico Innovagroup S.r.l. with its principal headquarters in Brescia, Italy. The definitive agreement encompasses the license of the company's liquid insulin mouth rinse solution for a period of 15 years in the European market in exchange for milestone payments and a...